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INTRODUCTION 
Most observers predict significant health-related gains from genomics 
research.  Policy and legal decisions made by government institutions, 
the courts and legislatures have the potential to make a significant 
impact on both the quantity and quality of effective and innovative 
healthcare-related products ultimately derived from the vibrant genomics 
research enterprise.  In particular, the careful management of the 
intellectual property (IP) aspects of this promising area of research will 
be necessary to maximise scientific progress, provide appropriate 
incentives for investment, and ultimately ensure optimal public benefit. 
It is the mission of the US National Institutes of Health (NIH), which is 
comprised of 27 individual institutes and is an agency of the US 
Department of Health and Human Services, to facilitate the translation 
of basic biomedical research discoveries into useful healthcare services 
and products.  Within the NIH, the National Human Genome Research 
Institute (NHGRI) is the agency’s lead entity for advancing human 
health through genetic research.  
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Through its stewardship of an array of infrastructure and research 
projects, including several innovative public-private consortia efforts, the 
NHGRI seeks to contribute to the genomic tools, data and knowledge 
bases.  In general, I believe that scientific progress in this still young field 
will be best served by early, open and continuing access to: i) 
comprehensive, high-quality data sets containing basic biological and 
biochemical data; and ii) critical biological materials such as animal 
models and genes.  Data such as the complete nucleotide sequence of 
many different organisms’ genomes, information on genetic variation 
within and among populations, and results on how gene expression is 
regulated at the cellular and molecular level are often referred to as ‘pre-
competitive’ information, and in my view should be made rapidly 
available to all, without restrictions on use.  Adherence by data and 
resource producers and users to this simple strategy should ensure that 
industry and academic researchers will be able to build upon this strong 
foundation.  
At the NIH we are expected to support basic scientific discovery whilst 
simultaneously facilitating the appropriate commercial research and 
development of the results of our formidable research programs.  A 
sizeable number of end users for these resource projects are employed 
with private sector companies.  For this constituency the terms 
governing the data use, data release, the sharing and distribution of 
research resources and intellectual property rights of derivative 
inventions are of particular importance.  Policies that limit companies’ 
ability to file patent applications or licence downstream uses could end 
up having an unintended inhibitory effect on the development of 
biomedical products.  Government policies need to balance the 
important dual goals of continuing to rapidly place huge amounts of data 
in the public domain and encouraging restriction-free sharing of 
genomic tools, whilst also ensuring that more applied inventions, 
notably those closer to being an actual product, can be patented.  US 
taxpayers, and especially patients, would like the government to 
appropriately foster the commercialisation of promising inventions 
derived from use of the data and reagents generated by these efforts.  
Currently, the NHGRI is actively involved in the development and 
vetting of policy options aimed at ensuring that genomic tools, resources 
and databases of genomic information are used in a manner that 
promotes scientific research and the practice of medicine.  
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Relevant policies implemented by NIH-supported public private 
consortia efforts such the International Human Genome Sequencing 
Consortium (IHGSC),2 the Trans-NIH Mouse Initiative,3 the 
Mammalian Gene Collection (MGC)4 and the International Haplotype 
Map Project (HapMap)5 are specifically covered in this review. 
THE NATIONAL HUMAN GENOME RESEARCH 
INSTITUTE: WHERE HAVE WE COME FROM AND 
WHERE ARE WE GOING?  
Where have we come from?  As leader in the international Human 
Genome Project (HGP), NHGRI has learned a great deal about how to 
coordinate and manage an international, geographically dispersed and 
extremely complex ‘community resource project’ (though this term was 
not in our lexicon at the time).  A decision on how to handle the 
prepublication release of HGP sequence data was made early on in the 
project, and a policy was put in place in 1997; a year prior to the start of 
the major large-scale sequencing phase.  The NHGRI’s data release and 
data deposition policy for DNA sequence information was designed ‘to 
make sequence data available to the research community as possible for 
free, unfettered use’.6  One of many other innovations of the HGP was 
the decision to include a research program on the ethical, legal and social 
issues (ELSI) arising from the study of the human genome.  ELSI 
research projects, including studies on the patenting and licensing of 
gene patents and diagnostic tests, were funded alongside the technology 
development, mapping and sequencing projects.  
In spring 2003 the International Human Genome Sequencing 
Consortium (IHGSC) celebrated the completion of the sequencing of 
the human genome; a milestone that, by a happy coincidence, occurred 
                                                        
2 NHGRI, ‘International Consortium Completes Human Genome Project’ (Press Release, 14 
April 2003) <http://www.genome.gov/11006929>; Human Genome Resources 
<http://www.ncbi.nlm.nih.gov/genome/guide/human/>. 
3 Trans-NIH Mouse Initiative 
<http://www.nih.gov/science/models/mouse/sharing/1.html>. 
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5 International HapMap Project <www.hapmap.org>. 
6 NGHRI, Policy on Release of Human Genomic Sequence Data 
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during the 50th anniversary year of Watson and Crick’s seminal 
discovery of the structure of DNA.  In anticipation of the ‘what’s next’ 
question, the NHGRI had invested in a deliberate, transparent and in-
depth consultation process, lasting almost two years, with the extended 
genetics community about its future.  With the help of patient advocates, 
ethicists, biotechnology company executives and healthcare 
practitioners, a consensus began to emerge as to which projects should 
be taken on by the NHGRI over the next decade.  
In a paper entitled ‘A Vision for the Future of Genomics Research’7 
published in April 2003, the leaders of NHGRI outlined a series of 
Hilbertian8 grand challenges.  Several of these challenges concern policy 
development.  Both the creators and end users of the fruits of genomic 
research need to be actively involved in the development and vetting of 
policy options so that practical solutions ones that facilitate the extensive 
use of genomic information in laboratory and clinical settings can be 
implemented.  Which policy issues are expected to have the greatest 
impact on whether or not citizens of the globe will realise benefits from 
genomics research in the future?  Among the critical ones are data 
release, data and resource sharing, and patent and licensing policies.  The 
remainder of this article focuses on the specifics of the intellectual 
property, data release, and research tool and data sharing policies in use 
for several NHGRI-funded genomics projects.  Lastly, an overview of 
some patent and licensing-related issues that have emerged in the 
genomics field is provided, together with a brief summary of several 
possible legislative and policy fixes for these thorny IP-related problems.  
GENOMICS COMMUNITY RESOURCE PROJECTS  
In an important recent international meeting to discuss data release for 
such enterprises, the concept of a ‘community resource project’ was 
born.  This is defined as ‘a research project specifically devised and 
implemented to create a set of data, reagents or other materials whose 
primary utility will be as a resource for the broad scientific community’.9 
                                                        
7 FS Collins et al, ‘A Vision for the Future of Genomics Research’ (2003) 422 Nature 1–13. 
8 D Hilbert, ‘Mathematical Problems’ (1902) 8 Bulletin of the American Mathematical Society 437–79. 
9 Wellcome Trust, Sharing Data from Large-Scale Biological Research Projects: A System of Tripartite 
Responsibility (Report of a meeting organised by the Wellcome Trust, Fort Lauderdale, 14–15 
January 2003). 
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Box 1 provides examples of several large-scale genomics enterprises that 
aim to produce data or create valuable scientific reagents of broad 
potential utility.  Many of the collaborators in these projects are small- 
and medium-sized private sector biotechnology and biopharmaceutical 
companies and large global pharmaceutical giants; however, academic 
centers have generally played a more major role.  
Box 1. Examples of Genomics Community Resource Projects 
à International Human Genome Sequencing Consortium 
(IHGSC)/Human Genome Project (HGP):10  
large-scale DNA mapping and sequencing of the human genome. 
à Mouse Genome Sequencing Consortium (MGSC):11  
MGSC - large-scale DNA mapping and sequencing of the Mus 
musculus (mouse) genome. 
à Rat Genome Sequencing Consortium (RGSC):12   
large-scale DNA mapping and sequencing of the Rattus norvegicus 
(rat) genome. 
à The SNP Consortium (TSC):13 discovery and characterisation of 
two million single nucleotide polymorphisms (SNPs) in the human 
genome; primarily a private sector initiative with some limited NIH 
involvement. 
à Trans-NIH Mouse Initiative:14 a group of initiatives for the creation 
and distribution of mouse genomic resources such as mutant mice, 
phenotypic and genotypic information and functional genomic data. 
à Mammalian Gene Collection (MGC):15  
development and distribution of a complete collection of full-length 
cDNAs for all known mouse, rat and human genes. 
                                                        
10 NHGRI, ‘International Consortium Completes Human Genome Project’ (Press Release, 14 
April 2003) <http://www.genome.gov/11006929>; Human Genome Resources 
<http://www.ncbi.nlm.nih.gov/genome/guide/human/>. 
11 Mouse Genome Sequencing Consortium (MGSC) <http://www.genome.gov/10001859>.  
12 Rat Genome Sequencing Consortium (RGSC) <http://www.genome.gov/11511308>. 
13 The SNP Consortium <http://snp.cshl.org>. 
14 Trans-NIH Mouse Initiative <http://www.nih.gov/science/models/mouse/>. 
15 Mammalian Gene Collection <http://mgc.nci.nih.gov>. 
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à International Haplotype Map Project (HapMap):16 creation of a 
haplotype map for the comprehensive study of human DNA 
variation among and between a diverse set of populations.  
à Encyclopaedia of DNA Elements (ENCODE):17 identification 
and characterisation of all the functional elements, such as 
regulatory sequences, encoded in the human DNA genome.  
 
Attendees of the 1996 Bermuda18 and the 2003 Fort Lauderdale19 
International Sequencing Consortium (ISC) meetings wholeheartedly 
agreed that the policy of rapid prepublication release of sequence data 
for projects, such as the HGP, should be extended beyond ‘simple’ 
sequence data to other types of more complex genomic data; for 
example, gene expression analysis/microarray data and protein structure 
information.  ‘The products of community resource projects have, over 
the past several years, become increasingly important as drivers of 
progress in biomedical research.  The scientific community will best be 
served if the results of community resource projects are made 
immediately available for free and unrestricted use by the scientific 
community to engage in the full range of opportunities for creative 
science.’20  The conclusion reached was that the architects of these other 
large-scale projects should seriously consider adopting the same data 
release policy.  Of course, the exact details of how, in what format and 
under what type of schedule these more complex data will be 
downloaded into public databases still needs to be defined by the 
domain experts.  For example, there are problems related to the optimal 
level and degree of validation needed for particular kinds of 
experimental data so that the data are useful and useable to other 
consortia scientists and non-consortia scientists. 
                                                        
16 International HapMap Project <www.hapmap.org>. 
17 Encyclopaedia of DNA Elements (ENCODE) <http://www.nhgri.nih.gov/10005107>.  
18 Dr Bentley, ‘Genomic Sequence Information Should be Released Immediately and Freely in 
the Public Domain’ (1996) 274 Science 533–4; Summary of Principles agreed at the International 
Strategy Meeting on Human Genome Sequencing (Bermuda, 25–28 February 1996).  
19 Wellcome Trust <http://www.wellcome.ac.uk/en/1/awtpubrepdat.html>. 
20 Wellcome Trust <http://www.wellcome.ac.uk/en/1/awtpubrepdat.html>. 
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The conclusions reached above by the ISC participants are consistent 
with the now seven-year-old NIH research tools policy officially called 
‘Sharing Biomedical Research Resources: Principles and Guidelines for 
Recipients of NIH Research Grants and Contracts’21 and the policies are 
also in line with the newer NIH policy on the sharing of data for 
extramural grantees and contractors.22  It is important to note that 
databases, along with research reagents, such as genes, vectors and 
antibodies, are considered to be research tools.  Under the policy, which 
went into effect on October 1, 2003, grantee institutions must submit 
proposed data-sharing plans in all grant applications that request US 
$500 000 or more per year in funds.  
SPECIAL CHALLENGES IN ACHIEVING OPEN DATA 
ACCESS: THE SNP CONSORTIUM AND THE HAPMAP 
PROJECTS  
The SNP Consortium (TSC) is a non-profit foundation that focused on 
discovering single point mutations in the human genome called single 
nucleotide polymorphisms (SNPs).  It was formed in 1999 with a mix of 
public and private funds, and the final data release occurred last 
September.  Its mission was to ‘develop up to 300 000 SNPs distributed 
evenly throughout the human genome and to make the information 
related to these SNPs available to the public without intellectual 
property restrictions’.23  The main idea behind the unique structuring of 
the consortium was that it made sense to have all interested parties, 
which included large pharmaceutical companies such as 
GlaxoSmithKline and charities such as the Wellcome Trust, share the 
risk and expense of developing a high-quality publicly available human 
SNP data set.  Many companies participated even though they were not 
given any special use of, or early access to, the data.  Nonetheless, clearly 
the private sector felt that the effort was worth the investment.  
The TSC members agreed to adopt a policy of waiving the right to 
receive patent protection on the raw SNP data and agreed to publish the 
                                                        
21 Report of the NIH Working Group on Research Tools, presented to the Advisory Committee to the 
Director (4 June 1998) <http://www.nih.gov/news/researchtools/>. 
22 NIH, Data Sharing Information <http://grants2.nih.gov/grants/policy/data_sharing/>. 
23 The SNP Consortium <http://snp.cshl.org>. 
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mapped SNPs as quickly as was feasible.  A legal instrument called a 
Statutory Invention Registration (SIR) was used in a defensive tactic to 
guard against those who might try to file patent applications on identical 
SNP data in advance of its public deposition.  SIRs were filed on the 
data as it was generated and then those SIRs were abandoned once the 
validated SNP information was downloaded to the TSC website every 
three months.24  
The goal of the HapMap consortium-based effort is to determine the 
common patterns of sequence variation in the human genome.25  
Because de novo mutations occur relatively rarely in human populations 
any new allele that does arise will ‘travel’ with other nearby alleles within 
a continuous block of genomic DNA on the particular chromosome.  
These common sets of alleles are called haplotypes.  At present the 
genotyping of hundreds of samples and the construction of detailed 
haplotype maps is being carried out on set of DNA specimens from 
populations with ancestry from various regions in Asia, Africa and 
Europe.26  
‘The [HapMap] project is committed to rapid and complete data release, 
and to ensuring that project data remain freely available in the public 
domain at no cost to users.’27  A legal review of potential intellectual 
property problems with the project raised one major concern: it would 
be theoretically possible for an unscrupulous company or entity to add 
on a trivial amount of information to the published HapMap data and 
then attempt to secure ‘parasitic’ patent claims such that all others would 
be prohibited from using the original public data.  This scenario along 
with other related concerns and a desire to be in harmony with earlier 
community resource projects, led the consortium members to agree 
upon a new data release and data use policy.  Under the policy, users of 
HapMap data can file patent applications on associations they uncover 
or verify between particular SNPs and disease and/or disease 
susceptibility.  The only caveat is that the owner or assignee of the 
                                                        
24 The SNP Consortium, Frequently Asked Questions <http://snp.cshl.org/about/faq.shtml>. 
25 International HapMap Project <www.hapmap.org>. 
26 The International HapMap Consortium, ‘International HapMap Consortium Paper’ (2003) 
426 Nature 789–96. 
27 The International HapMap Consortium, ‘International HapMap Consortium Paper’ (2003) 
426 Nature 789–96. 
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patents cannot try to limit or prevent other users from enjoying full and 
unrestricted access to the HapMap data.  A click-on licence agreement 
describing the details of the policy is posted on the HapMap project 
website.28  Users must agree to the conditions of the online policy before 
they are permitted to access or download HapMap data.  
The HapMap participants, similarly to the members of TSC, agreed that 
SNPs, genotypes and haplotype data of unknown specific utility are not 
inventions and therefore are not appropriate subject matter for 
patenting.29  Conversely, an SNP or haplotype that is strongly associated 
with a disease or medically important phenotype, such as susceptibility 
to diabetes or a poor response to a particular chemotherapy drug, would 
clearly have a specific utility and be patentable.  However, neither TSC 
nor the HapMap projects include phenotype or disease association 
studies.  
THE SHARING OF VALUABLE RESEARCH 
REAGENTS: MOUSE RESOURCES AND THE 
MAMMALIAN GENE COLLECTION  
The NIH encourages and actively supports the sharing of resources such 
as inbred mouse strains, genetically modified mice as well as the DNA 
vectors and murine embryonic stem cells that must be used to generate 
useful model knockout lines.  To facilitate the timely and efficient 
development and distribution of a wide array of mouse resources the 
NIH decided to place a number of related projects under the 
administrative management of a new umbrella program called the Trans-
NIH Mouse Initiative.30  Beginning in 1998, workshops were convened 
to bring together diverse members of mouse and larger scientific 
community, as well as program staff from many NIH institutes, in order 
to research agreement on the key priorities for the initiative.  
Coordination and oversight of the many program such mutagenesis and 
phenotyping studies, genomic sequencing and the creation of mouse 
repositories such as the Mutant Mouse Regional Resource Centers is 
                                                        
28 International HapMap Project <www.hapmap.org>. 
29 International HapMap Project <www.hapmap.org>. 
30 Trans-NIH Mouse Initiative <http://www.nih.gov/science/models/mouse/>. 
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carried out by a Trans-NIH Mouse Genomics and Genetics Resources 
Coordinating Group.  
In 2003, the coordinating group also wrote a policy document entitled 
‘NIH Statement on Sharing and Distributing Mouse Resources’.31  As a 
result of this policy, not-for-profit entities may obtain materials for use 
in non-commercial research using a standard Material Transfer 
Agreement (MTA).  Importantly, the MTA cannot contain reach-
through licensing terms, nor can it contain provisions that are more 
restrictive than those included in the widely used Simple Letter 
Agreement (SLA)/Uniform Biological Materials Transfer Agreements 
(UBMTA).32  In most cases the decision to seek patent protection on a 
particular genetically modified mouse is entirely up to the grantee or 
contractor, as is their right under the US 1980 Bayh Dole Act.  
The terms of some NIH funding arrangements for projects under the 
Trans-NIH Mouse Initiative do, however, contain an exception, known 
as a Determination of Exceptional Circumstances (DEC).  US 
government grantees and contractors do not obtain title to inventions 
when the government makes a ‘determination of exceptional 
circumstances’.33  A DEC removes the standard right of ownership 
usually retained by the funded institution for inventions made by their 
employees when the research was funded, partially or in whole, with 
government monies.  This administrative and legal tool is only used for 
programs in which the main goals are to create data and/or resources 
that are to be made widely available with minimal restrictions on their 
use.  NIH’s intention to utilise a DEC for a new program is always 
announced in advance of the award of a grant or contract.  Regardless of 
whether or not a specific mouse mutant or mouse resource is patented 
those interested in using the animals or materials for commercial 
purposes must negotiate a licence with the owner.  
Another important genomics research tool initiative called the 
Mammalian Gene Collection (MGC) program, which began in 1999, 
represents yet another unique undertaking by NIH.  Its remit is to create 
                                                        
31 NIH, Statement of Sharing and Distributing Mouse Resources 
<http://www.nih.gov/science/models/mouse/sharing/>. 
32 Uniform Biological Materials Transfer Agreement (UBMTA) 
<http://ott.od.nih.gov/NewPages/UBMTA.pdf>. 
33 As set forth at: 35 USC § 202(a) (1994). 
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a public collection of affordable, sequence-verified full-length 
complementary DNAs (cDNAs) for every known mouse and human 
gene, and a subset of rat genes.  Feedback solicited from the NIH 
intramural and extramural communities at the time revealed that the lack 
of reasonably priced, freely available and sequence-verified ‘correct’ 
cDNA clones was indeed slowing down many research projects.  After a 
careful study and review of the various options, the NIH decided to 
fund and handle the coordination for the MGC initiative.  This was 
fortunate as perhaps no other entity had the experience, financial 
resources or technical wherewithal to competently take on and 
successfully complete such a project.  
Like some programs managed under the Trans-NIH Mouse Initiative, 
the MGC request for funding proposals contained a DEC.  The MGC 
also works closely with related projects to create collections of Xenopus 
and zebrafish full-length cDNAs.  Not only does the MGC make 
available high- quality and modestly priced cDNAs but buyers are free to 
use the clones for research purposes and there are no onerous IP or 
reach-through licensing terms whatsoever.   
Today the MGC physical clones are currently available to both non-
commercial and commercial scientists via the IMAGE consortium 
distributors for a modest fee.34  In addition, as a result of NIH partner 
Invitrogen’s open architecture licensing policy for its Gateway® and 
Superscript technologies, as is also outlined in an open-access agreement 
with NIH, academic and government purchasers of the system are 
permitted to share MGC clones made using the company’s technologies 
and/or genes cloned into Gateway® vectors with others for research 
purposes.  The HGP, the HapMap, the Trans-NIH Mouse Initiative and 
the MGC are key components of the burgeoning publicly available 
collections of scientific resources (mainly data and research reagents) 
that are supported by NHGRI and other NIH Institutes.  The creation 
of additional valuable research reagents and data sets, available to all, for 
the global genomics-based research toolbox is a goal that cross-cuts all 
of NHGRI’s community resource projects.  
                                                        
34 Mammalian Gene Collection, Where to Buy <http://mgc.nci.nih.gov/Info/Buy>. 
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NIH PATENT POLICY AND GENOMICS-SPECIFIC 
INTELLECTUAL PROPERTY ISSUES  
As a result of the 1986 Federal Technology Transfer Act (FTTA) American 
government research laboratories such as NIH were given a statutory 
mandate to encourage and facilitate the efficient and expeditious transfer 
of promising new technologies invented in NIH intramural labs to 
companies for further development and commercialisation.  Over the 
next few years government agencies created technology licensing offices 
and began to develop and implement patent and licensing policies.  The 
current version of the NIH Patent Policy was adopted in 1995 and 
includes the following recommendations:35  
à Seek patent protection on biomedical technologies 
when having IP rights will facilitate the availability of 
the technology for research or commercial use. 
à Seek patent protection for inventions when IP rights are 
necessary to attract commercial partners and further 
R&D is required.  
à Do not seek patent protection for technologies if no 
further R&D is required and the invention has no 
obvious preventative, diagnostic/prognostic and/or 
therapeutic use (for example, has no commercial or 
public health value).  
à Do not unduly delay or avoid the public disclosure of 
research results because of anticipated future patent 
filings (reasonable delays of one to several months are 
permitted).  
The above policy does not distinguish between different types of 
inventions; it is purposefully general in nature so that it can be applied to 
all NIH-developed inventions.  
Earlier in 2004, the NIH opted to publish a guidance document 
specifically aimed at outlining what are considered to be our own 
internal best practices for the handling of genomic inventions.  This new 
draft publication was entitled ‘Best Practices for the Licensing of 
                                                        
35 United States Public Health Service Technology Transfer Manual, Chapter 200: PHS Patent Policy. 
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Genomics Inventions’,36 and it summarised the guiding principles used 
by licensing specialists at the NIH when they negotiate deals.  One of 
the most provocative, and in my view the most sensible, suggestions had 
to do with the licensing of diagnostic applications of genomic 
inventions: entities are strongly encouraged to non-exclusively licence 
diagnostic inventions or, at a minimum, to grant only narrow exclusive 
licences for these kinds of inventions (limiting the licence to particular 
fields of use such as one type of technology platform, one or a few 
disease indication(s) and/or certain geographic regions).  These 
suggestions are similar to those put forward by the Nuffield Council on 
Bioethics in their 2002 discussion paper.37  
It is important to encourage the commercialisation of as many types of 
clinical diagnostic tools and tests as possible, as competition in the 
marketplace should translate to an increase in the number of innovative 
and affordable products available to patients and their physicians.  By 
publishing practical details on how we at NIH handle the licensing of 
various types of genomic inventions, we hope to give academics ideas 
for how they might handle the licensing of similar inventions within 
their own universities and hospitals. 
To get a patent in the US one must show that the invention is: useful, 
non-obvious or inventive, and novel.  The Nuffield Council on 
Bioethics report38 on the ethics of patenting DNA discusses several 
important issues with regard to the legal concepts of utility and 
inventiveness.  In general, the European Patent Office (EPO) holds 
patent applications to a higher standard of inventiveness than does the 
US Patent and Trademark Office (USPTO).  The EPO states ‘the 
isolation of DNA sequences that have a structure closely related to 
existing sequences in which the function is known is not inventive’.39  
Using computational tools to identify homologues and assign 
hypothetical functions, so-called in silico analysis, to a DNA sequence 
                                                        
36 Best Practices for the Licensing of Genomic Inventions, 69 Federal Regulations 67747–8 (2004). 
37 Nuffield Council on Bioethics, The Ethics of Patenting DNA: A Discussion Paper (July 2002) 
<www.nuffieldbioethics.org>. 
38 Nuffield Council on Bioethics, The Ethics of Patenting DNA: A Discussion Paper (July 2002) 
<www.nuffieldbioethics.org>. 
39 Nuffield Council on Bioethics, The Ethics of Patenting DNA: A Discussion Paper (July 2002) 
<www.nuffieldbioethics.org>. 
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would not be considered inventive in Europe; whereas according to the 
USPTO rules the use of non-laboratory bench computer-based methods 
would not necessarily exclude the granting of a patent for a gene on the 
basis of non-obviousness.40  Fortunately, the USPTO issued revised 
utility guidelines in early 2001.  Inventions now must show a ‘specific 
and substantial and credible utility’.41  This is certainly an improvement 
but only one specific, substantial and credible utility per DNA sequence 
is needed and so a composition-of-matter patent on a gene sequence can 
easily come to encompass new uses discovered long after the initial 
filing, even if those uses were not known at the time or not disclosed in 
the original patent.42  In my opinion this is unfair as it penalises those 
who do the hard work of figuring out the biological function(s) of genes 
and proteins.  The USPTO utility guidelines should be modified to 
eliminate this ‘loophole’. 
Box 2 contains information on three published reports and one ongoing 
study, all of which focus on gene patent and/or genomic patent and 
licensing issues.  Patents are a lynchpin for successful commercial 
entities in the genomics field; they are a driving force behind innovation 
and a guarantee that the discoveries will be fully disclosed and speedily 
delivered for scientific and societal benefit.  Nonetheless, patents with 
overly broad claims, as well as those with unsubstantiated data or a 
complete lack of data for the specific claimed uses, should not be 
allowed to issue.  Also, there is the issue of the exponentially growing 
body of patents in the genomics area; this has led to a so-called patent 
‘thicket’43 problem.  To ensure their freedom to operate in a complex 
marketplace many companies often must licence a large range of 
overlapping and related patents; the high licensing and transactional 
costs in terms of both time and money could be causing some 
companies to abandon efforts to try to commercialise needed diagnostic 
and therapeutic products.  
                                                        
40 Nuffield Council on Bioethics, The Ethics of Patenting DNA: A Discussion Paper (July 2002) 
<www.nuffieldbioethics.org>. 
41 USPTO Utility Examination Guidelines, 66 Federal Regulations 1092 (2001). 
42 E Marshall, ‘Patent on HIV Receptor Provokes an Outcry’ (2000) 287 Science 1375–7. 
43 MA Heller and RS Eisenberg, ‘Can Patents Deter Innovation?  The Anticommons in 
Biomedical Research’ (1998) 280 Science 698–701. 
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Box 2. Recent Gene Patent and Intellectual Property Policy 
Reports  
à  Nuffield Council on Bioethics, The Ethics of Patenting DNA: a 
Discussion Paper (July 2002) <www.nuffieldbioethics.org>. 
à The Royal Society, Keeping Science Open: the Effects of Intellectual 
Property on the Conduct of Science (April 2003) 
<www.royalsoc.ac.uk>. 
à The Australian Law Reform Commission, Gene Patenting and 
Human Health Discussion Paper (March 2004)  
<www.austlii.edu.au/au/other/alrc/publications/dp/68/>. 
à US National Academy of Sciences, Intellectual Property Rights in 
Genomics and Protein-Related Research (Report expected in March 
2005)<www.nationalacademies.org> (under Current Projects 
tab).  
 
The sequencing and public disclosure of the human genome and the 
gearing up of several other genomics community resource projects has 
effected a shift in the commercial landscape.  Over the last few years, 
with sequence information, SNP information and soon haplotype data 
publicly available at no cost, a number of companies have exited the 
genomic information database subscription business.  Not surprisingly, 
many of these same ‘content’ companies are in the process of 
transforming themselves into biopharmaceutical companies.  
Consequently, they are now focusing exclusively on activities such as 
functional genomics, target validation and the screening of small 
molecular libraries in their quest to identify promising lead molecules.  
Finally we must ponder the ramifications of a recent US court ruling.  
Historically, biotechnology and pharmaceutical companies have almost 
never sued academic investigators for patent infringement, as long as no 
active selling was occurring, even if the not-for-profit scientists were 
using the company’s patented invention.  The harsh reality of the lack of 
a formal research exemption in US law was brought to everyone’s 
attention with the Madey v Duke44 court decision.  As succinctly stated by 
                                                        
44 Madey v Duke University 307 F 3d 1351 (2002). 
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University of Michigan law professor Rebecca Eisenberg, ‘[t]he recent 
rejection by the Court of Appeals for the Federal Circuit of an 
“experimental use defence” to a patent infringement lawsuit against 
Duke University. . . is an alarming wake-up call to the academic 
community’.45  That court decision now makes it possible, and perhaps 
even likely, that cash-strapped or aggressive companies with no 
immediate revenue streams will assert their patent rights against 
university researchers.46  Rather than taking a wait-and-see approach, an 
attempt should be made by lawmakers and academics to create a true 
research exemption in US patent law.  
EXPERT OPINION  
The free sharing and wide dissemination of pre-competitive genomic 
data and research resources has numerous significant benefits to 
research institutions, companies, scientists and the general public. 
Therefore, we do not support the idea of the US enacting sui generis 
database protection legislation similar to the Database Directive passed 
in the EU.47  Share and share alike ‘open source code’ - like data release 
and use policies such as the ones mentioned in this article inevitably 
encourage researchers to undertake different scientific approaches as 
they attempt to unravel the intricacies of complex biological systems.  
The following are just a few of the benefits that result from the creation 
and maintenance of centralised databases and repositories: improved 
ease of access; avoidance of duplication of effort; and more efficient use 
of limited research funds.  Projects such as the IHGSC, International 
Mouse Genome Sequencing Consortium (IMGSC), International Rat 
Genome Sequencing Consortium (IRGSC), TSC and HapMap have 
unequivocally demonstrated the usefulness of having open access 
comprehensive databases that contain vast quantities of genomic 
information.  
Initiatives such as the MGC and Trans-NIH Mouse Initiative have 
drawn attention to the immense value of research tools for aiding and 
                                                        
45 RS Eisenberg, ‘Patent Swords and Shields’ (2003) 299 Science 1018–19. 
46 C Dennis, ‘Geneticists Question Fees for Use of Patented “Junk” DNA’ (2003) 423 Nature 
105. 
47 EU Database Directive 96/9/EC (1996) 
<http://europa.eu.int/ISPO/infosoc/legreg/docs/969ec.html>. 
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accelerating scientific progress in all sectors: academic, government and 
commercial.  All of these projects bring together the collective financial 
and intellectual resources of many diverse partners, and result in 
efficiencies of operation, scale and speed not normally associated with 
government- or academic-backed endeavours.  Participants in Genomics 
Community Resource Projects are cognisant that the greatest 
opportunity for value creation using the data and research tools 
developed by consortia efforts will occur downstream from the 
discovery of basic genetic and biological information.  
CONCLUSION 
In summary: i) I hope that universities and others will follow the 
suggestions outlined in NIH’s new guidance document on the best 
practice for licensing genomic inventions; ii) I support the concept of 
enacting legislation to establish a formal research exemption for the non-
commercial research use of patented inventions and technologies by 
not-for-profit entities; iii) I support the idea of raising the utility ‘bar’ 
even higher than was done in the 2001 revisions of the USPTO’s utility 
guidelines for biotechnology inventions; and iv) I support the concept of 
compulsory licensing and/or compulsory sublicensing by patent holders 
of genomic/genetic diagnostic technologies and inventions.48  
Today it is much easier for scientists everywhere to rapidly build upon 
genomic research carried out by their colleagues.  We at NIH look 
forward to the establishment of additional public private partnerships 
that are dedicated to placing pre-competitive data in the public domain.  
As a leader in the fields of genetic research and genomic science, 
NHGRI will continue to help encourage policy debates and support 
research,49 which informs policy development, in order to facilitate the 
widespread use of genomic information in both research and clinical 
settings, and in order to facilitate the development of new genomics-
based products.  
                                                        
48 Proposed Genomic Research and Diagnostic Accessibility Act of 2002 (HR3967); T Abate, 
‘Do Patients Wrap Research in Red Tape’ San Francisco Chronicle, 25 March 2002.  
49 Example: request for application RFA-HG-04–004: Intellectual Property Rights in Genetics and 
Genomics <http://grants1.nih.gov/grants/guide/rfa-files/RFA-HG-04-004.html>.  
